Global Cancer Biomarkers Market Expected to Reach USD 89.5 Billion by 2033 - IMARC Group

November 13, 2024 | Healthcare

VIEW FULL TABLE OF CONTENTS

Global Cancer Biomarkers Market Statistics, Outlook and Regional Analysis 2025-2033

The global cancer biomarkers market size was valued at USD 31.3 Billion in 2024, and it is expected to reach USD 89.5 Billion by 2033, exhibiting a growth rate (CAGR) of 11.09% from 2025 to 2033.

Cancer Biomarkers Market

To get more information on the this market, Request Sample

The market is experiencing an increase in demand for specialized training programs targeted at strengthening pathology knowledge and expanding biomarker research, as well as supporting skill development and improving diagnostic accuracy and individualized treatment techniques. For example, in November 2020, Agilent Technologies Inc. launched the Biomarker Pathologist Training Program, a global initiative designed to empower pathologists to score biomarkers accurately and confidently. This program incorporates Agilent's expertise in companion diagnostics and partnerships with leading pharmaceutical companies, aiming to enhance pathologists' skills in biomarker interpretation and scoring techniques.

Moreover, business partnerships are increasingly important in promoting biomarker research and clinical advancement, as prominent firms combine expertise in next-generation sequencing and protein biomarker discoveries to drive innovation and improve diagnostic and therapeutic options. For instance, in January 2022, Illumina Inc., renowned for its pioneering work in next-generation sequencing (NGS), embarked on a significant collaborative endeavor by forming a co-development partnership with SomaLogic. This partnership represents a pivotal moment in the landscape of biomarker research and clinical advancements. Furthermore, cancer biomarker providers are concentrating on improving diagnostic accuracy and precision while adhering to healthcare standards for early identification and individualized therapy. This initiative promotes national healthcare goals and regulatory targets for better cancer management. The expanding usage of biomarker-based diagnostics provides an opportunity for enterprises to broaden their market reach and income. Furthermore, healthcare practitioners are favoring advanced biomarkers over traditional diagnostic procedures due to their more precise accuracy in detecting certain cancer types. For example, in the Asia Pacific region, increased biotechnology investments and the presence of significant firms such as BGI Genomics and WuXi AppTec are boosting the use of new cancer biomarkers, resulting in improved patient outcomes and competitive market dynamics.

Global Cancer Biomarkers Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest cancer biomarkers market share owing to the presence of a well-established healthcare infrastructure with advanced medical facilities, research centers, and academic institutions.

North America Cancer Biomarkers Market Trends:

A significant emphasis on customized medicine fuels the need for biomarker-driven approaches to patient treatment. For instance, in May 2023, Danaher Corporation, through its subsidiary Beckman Coulter, unveiled the DxI 9000 access immunoassay analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).

Europe Cancer Biomarkers Market Trends:

Collaborative projects such as the EU's Horizon 2020 program make substantial advances in biomarker-based cancer diagnoses in Europe. This encourages innovation in early diagnosis and treatment, establishing Europe as a leader in research-driven improvements in the industry.

Asia Pacific Cancer Biomarkers Market Trends:

In Asia Pacific, increased biotechnology investments are driving the market, with China investing in genomics research to improve cancer diagnoses. This regional commitment promotes biomarker discovery, resulting in tailored care and better patient outcomes.

Latin America Cancer Biomarkers Market Trends:

Latin America is making progress in cancer biomarker accessibility as healthcare infrastructure improves, notably in Brazil. Increased public and private investment enables improved diagnostic services, which drives market development and improves patient care alternatives in the region.

Middle East and Africa Cancer Biomarkers Market Trends:

Strategic relationships, such as those between the UAE and worldwide biotech enterprises, are driving market expansion in the Middle East and Africa. These collaborations enhance biomarker-based diagnostic technologies, hence increasing cancer detection and treatment capacities in the region's healthcare system.

Top Companies Leading in the Cancer Biomarkers Industry

Some of the leading cancer biomarkers market companies include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Qiagen N.V., Sino Biological Inc., and Thermo Fisher Scientific Inc., among many others. For example, in July 2020, Thermo Fisher Scientific signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and applied to the Ministry of Health, Labor and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan.

Global Cancer Biomarkers Market Segmentation Coverage

On the basis of profiling technology, the market has been bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics. Omic technologies assess cancer's molecular makeup and imaging technologies provide non-invasive tumor viewing. Furthermore, immunoassays identify cancer markers, and cytogenetics identifies chromosomal mutations.
Based on the biomolecule, the market is categorized into genetic biomarkers, protein biomarkers, and glyco-biomarkers, amongst which genetic biomarkers dominate the market. Genetic biomarkers provide information about an individual's genetic susceptibility, mutations, and variances that contribute to illness development.
On the basis of the cancer type, the market has been divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. Among these, lung cancer exhibits a clear dominance in the market. Lung cancer has a high global prevalence, being among the top causes of cancer-related fatalities. The significant link between lung cancer and smoking, combined with environmental variables, adds to its widespread prevalence.
Based on the application, the market is bifurcated into diagnostics, prognostics, risk assessment, drug discovery and development, and others. Diagnostics assist early cancer detection by identifying biomarkers. Prognostics measure disease progression and patient outcomes. Risk assessment reveals those who are more likely to get cancer. Biomarkers are used in drug discovery and development to build tailored and effective medicines, hence improving treatment techniques and patient outcomes.
On the basis of the end user, the market is segmented into hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others. Cancer biomarkers are used in hospitals to provide accurate diagnoses and individualized therapy. Academic and research institutes prioritize biomarker development and validation. Biomarkers are used in ambulatory surgical centers to guide targeted surgical procedures. Diagnostic laboratories use advanced biomarker testing to identify and monitor cancer accurately.

Report Features	Details
Market Size in 2024	USD 31.3 Billion
Market Forecast in 2033	USD 89.5 Billion
Market Growth Rate 2025-2033	11.09%
Units	Billion USD
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Profiling Technology Biomolecule Cancer Type Application End User Region
Profiling Technologies Covered	Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics
Biomolecules Covered	Genetic Biomarkers, Protein Biomarkers, Glyco-Biomarkers
Cancer Types Covered	Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others
Applications Covered	Diagnostics, Prognostics, Risk Assessment, Drug, Discovery and Development, Others
End Users Covered	Hospitals, Academic and Research Institutions, Ambulatory Surgical Centers, Diagnostic Laboratories, Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Qiagen N.V., Sino Biological Inc.,Thermo Fisher Scientific Inc.,etc.
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Browse IMARC Related Reports on Cancer Biomarkers Market

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Cancer Biomarkers Market Expected to Reach USD 89.5 Billion by 2033 - IMARC Group

Purchase Options New Year Sale

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.